BioVie

BioVie is a clinical-stage biotechnology company with a mission to unlock the science of longevity by targeting the inflammatory and metabolic roots of age-related diseases. Its core strategy is built around bezisterim (NE3107), a novel, orally-administered small molecule designed to selectively modulate neuroinflammation and improve insulin sensitivity in the brain. The company has advanced bezisterim into Phase 2/3 trials for Alzheimer's disease and Phase 2 studies for Parkinson's disease and Long COVID, while concurrently exploring its epigenetic impact on aging. A second clinical program, BIV201, is being developed for the treatment of refractory ascites due to liver cirrhosis.

Centered on bezisterim (NE3107), a novel small molecule platform designed for selective modulation of inflammatory pathways (ERK, NF-κB) and insulin sensitization, with exploration of epigenetic effects via DNA methylation.

In Alzheimer's, bezisterim competes with approved anti-amyloid biologics but differentiates via oral administration and a complementary anti-inflammatory mechanism. In Parkinson's and Long COVID, it faces less direct competition but must prove efficacy in crowded and nascent fields, respectively. BIV201 has no direct pharmacologic competitors in ascites, competing against invasive procedures.